Jefferies Maintains a 'Buy' on Medivation (MDVN)); PREVAIL Trial Design Increases Odds of Success
Get Alerts MDVN Hot Sheet
Price: $81.44 --0%
Rating Summary:
12 Buy, 17 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 2 | New: 35
Rating Summary:
12 Buy, 17 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 2 | New: 35
Join SI Premium – FREE
Jefferies maintains a 'Buy' on Medivation (NASDAQ: MDVN) price target of $95.00.
Analyst, Biren Amin, said, "Interest has increased in MDVN's PREVAIL study in 1,680 chemo-naive CRPC patients after Johnson & Johnson (NYSE: JNJ) release of the '302 data in a similar setting. After JEF-hosted investor meetings w/ mgmt, we learned a critical difference in the design of the PREVAIL Phase III trial which increases its odds of success/minimizes risk of postprogression contamination. MDVN shares may appreciate after JNJ '302 data at ASCO and into PREVAIL interim data in Q2 '13."
For an analyst ratings summary and ratings history on Medivation click here. For more ratings news on Medivation click here.
Shares of Medivation closed at $73.56 yesterday.
Analyst, Biren Amin, said, "Interest has increased in MDVN's PREVAIL study in 1,680 chemo-naive CRPC patients after Johnson & Johnson (NYSE: JNJ) release of the '302 data in a similar setting. After JEF-hosted investor meetings w/ mgmt, we learned a critical difference in the design of the PREVAIL Phase III trial which increases its odds of success/minimizes risk of postprogression contamination. MDVN shares may appreciate after JNJ '302 data at ASCO and into PREVAIL interim data in Q2 '13."
For an analyst ratings summary and ratings history on Medivation click here. For more ratings news on Medivation click here.
Shares of Medivation closed at $73.56 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies Starts Zoom Video (ZM) at Hold
- China Resources Beer Holdings Co Ltd. (291:HK) (CRHKY) PT Raised to HK$44.67 at Jefferies
- JPMorgan Upgrades Mersana (MRSN) to Neutral, 'thinking through Expectations for Midyear B7-H4 Updates'
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!